{{Drugbox
| Verifiedfields = 
| Watchedfields = 
| verifiedrevid = 
| IUPAC_name = (8''S'',11''R'',13''S'',14''S'',17''S'')-17-Hydroxy-13-methyl-11-[4-[methyl(propan-2-yl)amino]phenyl]-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[''a'']phenanthren-3-one
| image = Toripristone.svg
| width = 250

<!--Clinical data-->
| tradename = 
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = 
| legal_UK = 
| legal_US = 
| legal_status = 
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion =

<!-- Identifiers -->
| CAS_number_Ref = 
| CAS_number = 91935-26-1
| CAS_supplemental = 
| class = 
| ATC_prefix = 
| ATC_suffix = 
| ATC_supplemental = 
| PubChem = 3086344
| IUPHAR_ligand = 
| DrugBank_Ref = 
| DrugBank = 
| ChemSpiderID_Ref = 
| ChemSpiderID = 2342997
| UNII = 711D76P884
| KEGG = 
| ChEBI = 
| ChEMBL = 2105533

<!--Chemical data-->
| C=31 | H=39 | N=1 | O=2
| SMILES = CC#C[C@@]1(CC[C@@H]2[C@@]1(C[C@@H](C3=C4CCC(=O)C=C4CC[C@@H]23)C5=CC=C(C=C5)N(C)C(C)C)C)O
| StdInChI_Ref = 
| StdInChI = 1S/C31H39NO2/c1-6-16-31(34)17-15-28-26-13-9-22-18-24(33)12-14-25(22)29(26)27(19-30(28,31)4)21-7-10-23(11-8-21)32(5)20(2)3/h7-8,10-11,18,20,26-28,34H,9,12-15,17,19H2,1-5H3/t26-,27+,28-,30-,31-/m0/s1
| StdInChIKey_Ref = 
| StdInChIKey = LOIYXTZQBQVHSF-PABOLRIOSA-N
| synonyms = RU-40555; 17β-Hydroxy-11β-[4-[methyl(1-methylethyl)amino]phenyl]-17α-(1-propyn-1-yl)estra-4,9-dien-3-one
}}

'''Toripristone''' ([[International Nonproprietary Name|INN]]) (developmental code name '''RU-40555''') is a [[synthetic compound|synthetic]], [[steroid]]al [[antiglucocorticoid]] as well as [[antiprogestogen]] which was never marketed.<ref name="HillMakin1991">{{cite book |author1= R.A. Hill |author2= H.L.J. Makin |author3= D.N. Kirk |author4= G.M. Murphy |title= Dictionary of Steroids |url= https://books.google.com/books?id=AI7EnUyeEtUC&pg=PA101 |date=23 May 1991 |publisher= CRC Press |isbn=978-0-412-27060-4 |pages= 101–}}</ref><ref name="WHO-INN">https://mednet-communities.net/inn/db/media/docs/p-innlist61.pdf</ref> It is reported as a potent and highly selective [[receptor antagonist|antagonist]] of the [[glucocorticoid receptor]] (GR) (K<sub>i</sub> = 2.4&nbsp;nM),<ref name="SteinigerKniess2008">{{cite journal |last1=Steiniger |first1=Bjorn |last2=Kniess |first2=Torsten |last3=Bergmann |first3=Ralf |last4=Pietzsch |first4=Jens |last5=Wuest |first5=Frank |title= Radiolabeled Glucocorticoids as Molecular Probes for Imaging Brain Glucocorticoid Receptors by Means of Positron Emission Tomography (PET) |journal= Mini-Reviews in Medicinal Chemistry |volume=8 |issue=7 |year=2008 |pages=728–739 |issn= 1389-5575 |doi= 10.2174/138955708784567403}}</ref><ref name="pmid12700716">{{cite journal |vauthors= Bachmann CG, Linthorst AC, Holsboer F, Reul JM |title= Effect of chronic administration of selective glucocorticoid receptor antagonists on the rat hypothalamic-pituitary-adrenocortical axis | journal = Neuropsychopharmacology | volume = 28 | issue = 6 | pages = 1056–67 | year = 2003 | pmid = 12700716 | doi = 10.1038/sj.npp.1300158 | url = }}</ref> though it also acts as an antagonist of the [[progesterone receptor]] (PR).<ref name="PhilibertCosterousse1991">{{cite journal|last1=Philibert|first1=D.|last2=Costerousse|first2=G.|last3=Gaillard-Moguilewsky|first3=M.|last4=Nedelec|first4=L.|last5=Nique|first5=F.|last6=Tournemine|first6=C.|last7=Teutsch|first7=G.|title=From RU 38486 towards Dissociated Antiglucocorticoid and Antiprogesterone|volume=19|year=1991|pages=1–17|issn=0301-3073|doi=10.1159/000419634}}</ref><ref name="FuHu2012">{{cite journal|last1=Fu|first1=Jing|last2=Hu|first2=Lina|last3=Huang|first3=Wei|last4=Zhu|first4=Huili|last5=Wang|first5=Qiushi|last6=He|first6=Fan|last7=Xie|first7=Lingxia|last8=Gan|first8=Xiaoling|last9=Huang|first9=Wei|title=Progesterone receptor antagonists and progesterone receptor modulators for endometriosis|year=2012|doi=10.1002/14651858.CD009881}}</ref>  The [[pharmacology|pharmacological]] profile of toripristone is said to be very similar to that of [[mifepristone]], except that toripristone does not bind to [[orosomucoid]] (α1-acid glycoprotein).<ref name="PhilibertCosterousse1991" /> The drug has been used to study the [[hypothalamic-pituitary-adrenal axis]] and has been used as a [[radiotracer]] for the GR.<ref name="pmid12700716" /><ref name="SteinigerKniess2008" /> Its INN was given in 1990.<ref name="WHO-INN" />

==See also==
* [[Aglepristone]]
* [[Lilopristone]]
* [[Onapristone]]
* [[Telapristone]]

==References==
{{Reflist|2}}

{{Glucocorticoid receptor modulators}}
{{Progesterone receptor modulators}}

[[Category:Alcohols]]
[[Category:Amines]]
[[Category:Antiglucocorticoids]]
[[Category:Antiprogestogens]]
[[Category:Estranes]]
[[Category:Ketones]]


{{steroid-stub}}
{{genito-urinary-drug-stub}}